WELIREG
-
KEYTRUDA Plus WELIREG Combination Adjuvant Therapy Shows 28% Reduced Risk of Recurrence or Death in Early-Stage Kidney Cancer
Merck’s new adjuvant therapy combining KEYTRUDA and WELIREG shows a 28% reduced risk of recurrence or death in early-stage kidney cancer patients. This promising data could significantly expand the use of Merck’s key oncology drugs, potentially reshaping the competitive landscape in the lucrative kidney cancer market. Analysts are scrutinizing long-term data and market implications.